Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NEONATAL RESPIRATORY TREATMENT

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. COPD

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. MALARIA TREATMENT

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. TUBERCULOSIS TREATMENT

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARDS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. CHRONIC WOUND HEALING

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. OTHERS

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

Chapter: 5 GLOBAL INHALED NITRIC OXIDE MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. By Application

5.2.4. U.S.

5.2.4.1. Market size and forecast, by Application

5.2.5. Canada

5.2.5.1. Market size and forecast, by Application

5.2.6. Mexico

5.2.6.1. Market size and forecast, by Application

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. By Application

5.3.4. Germany

5.3.4.1. Market size and forecast, by Application

5.3.5. France

5.3.5.1. Market size and forecast, by Application

5.3.6. UK

5.3.6.1. Market size and forecast, by Application

5.3.7. Italy

5.3.7.1. Market size and forecast, by Application

5.3.8. Rest of Europe

5.3.8.1. Market size and forecast, by Application

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. By Application

5.4.4. China

5.4.4.1. Market size and forecast, by Application

5.4.5. Japan

5.4.5.1. Market size and forecast, by Application

5.4.6. India

5.4.6.1. Market size and forecast, by Application

5.4.7. Australia

5.4.7.1. Market size and forecast, by Application

5.4.8. Korea

5.4.8.1. Market size and forecast, by Application

5.4.9. Rest of Asia-Pacific

5.4.9.1. Market size and forecast, by Application

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. By Application

5.5.4. Brazil

5.5.4.1. Market size and forecast, by Application

5.5.5. Saudi Arabia

5.5.5.1. Market size and forecast, by Application

5.5.6. South Africa

5.5.6.1. Market size and forecast, by Application

5.5.7. Rest of LAMEA

5.5.7.1. Market size and forecast, by Application

Chapter: 6 COMPANY PROFILES

6.1. NU-MED PLUS, INC.

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. GENOSYS INC.

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. PRAXAIR, INC.

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. AIR LIQUIDE S.A.

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. MALLINCKRODT PHARMACEUTICALS

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. SIGMA-ALDRICH CO. LLC.

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. NOVOTERIS, LLC

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. IKARIA CANADA INC.

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. GENO, LLC

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. PERMA PURE LLC

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments